Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor‑κB activation in a hypoxia‑inducible factor 1‑α dependent manner

Wang,GuoLiang; Sai,Ke; Gong,FangHe; Yang,QunYing; Chen,FuRong; Lin,Jian

doi:10.3892/mmr.2014.2052

Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor‑κB activation in a hypoxia‑inducible factor 1‑α dependent manner

Authors:
- GuoLiang Wang
- Ke Sai
- FangHe Gong
- QunYing Yang
- FuRong Chen
- Jian Lin
View Affiliations

Affiliations: Department of Neurosurgery, General Hospital of Guangzhou Military Commanding, Guangzhou, Guangdong 510010, P.R. China, The State Key Laboratory of Oncology in South China, Department of Neurosurgery, Sun Yat‑Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
Published online on: March 14, 2014 https://doi.org/10.3892/mmr.2014.2052
Pages: 1799-1805

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recently, mutations of the isocitrate dehydrogenase (IDH) 1 gene, which specifically occur in the majority of low‑grade and secondary high‑grade gliomas, have drawn particular attention of neuro‑oncologists. Mutations of the IDH1 gene have been proposed to have significant roles in the tumorigenesis, progression and prognosis of gliomas. However, the molecular mechanism of the role of IDH1 mutants in gliomagenesis remains to be elucidated. The present study, showed that forced expression of an IDH1 mutant, of which the 132th amino acid residue arginine is substituted by histidine (IDH1R132H), promoted cell proliferation in cultured cells, while wild‑type IDH1 overexpression had no effect on cell proliferation. Consistent with previous studies, it was also observed that expression of hypoxia‑inducible factor 1‑α (HIF1‑α) was upregulated in IDH1R132H expressing cells with the induction of vascular endothelial growth factor (VEGF) expression. However, knockdown of VEGF via small RNA interference had no significant influence on the cell proliferation induced by overexpression of IDH1R132H, implying that another signaling pathway may be involved. Next, forced expression of IDH1R132H was found to activate nuclear factor‑κB (NF‑κB), since the inhibitory IκB protein (IκBα) was highly phosphorylated and the NF‑κB p65 subunit was translocated into the nucleus. Notably, knockdown of HIF1‑α significantly blocked NF‑κB activation, which was induced by the overexpression of IDH1 mutants. In addition, expression of IDH1 mutants markedly induced the NF‑κB target gene expression, including cyclin D1 and E and c‑myc, which were involved in the regulation of cell proliferation. In conclusion, it was demonstrated that the IDH1 mutant activated NF‑κB in a HIF1‑α‑dependent manner and was involved in the regulation of cell proliferation.

View Figures

View References

1	Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
2	Balss J, Meyer J, Mueller W, et al: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116:597–602. 2008. View Article : Google Scholar : PubMed/NCBI
3	Watanabe T, Nobusawa S, Kleihues P and Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 174:1149–1153. 2009. View Article : Google Scholar : PubMed/NCBI
4	Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ichimura K: Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol. 29:131–139. 2012. View Article : Google Scholar : PubMed/NCBI
6	Ramachandran N and Colman RF: Chemical characterization of distinct subunits of pig heart DPN-specific isocitrate dehydrogenase. J Biol Chem. 255:8859–8864. 1980.PubMed/NCBI
7	Ichimura K, Pearson DM, Kocialkowski S, et al: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 11:341–347. 2009. View Article : Google Scholar : PubMed/NCBI
8	Hartmann C, Hentschel B, Wick W, et al: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 120:707–718. 2010. View Article : Google Scholar
9	Zhao S, Lin Y, Xu W, et al: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science. 324:261–265. 2009.PubMed/NCBI
10	Dang L, White DW, Gross S, et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI
11	Sahm F, Capper D, Pusch S, et al: Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry. Brain Pathol. 22:26–31. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hughes JM, Groot AJ, van der Groep P, et al: Active HIF-1 in the normal human retina. J Histochem Cytochem. 58:247–254. 2010. View Article : Google Scholar : PubMed/NCBI
13	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
14	Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 361:1058–1066. 2009. View Article : Google Scholar : PubMed/NCBI
15	Taylor CT: Interdependent roles for hypoxia inducible factor and nuclear factor-κB in hypoxic inflammation. J Physiol. 586:4055–4059. 2008.
16	Walmsley SR, Farahi N, Peyssonnaux C, et al: Hypoxia-induced neutrophil survival is mediated by HIF-1α-dependent NF-κB activity. J Exp Med. 201:105–115. 2005.
17	Bruning U, Fitzpatrick SF, Frank T, et al: NFkappaB and HIF display synergistic behaviour during hypoxic inflammation. Cell Mol Life Sci. 69:1319–1329. 2012. View Article : Google Scholar : PubMed/NCBI
18	Koong AC, Chen EY and Giaccia AJ: Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res. 54:1425–1430. 1994.
19	Kenneth NS and Rocha S: Regulation of gene expression by hypoxia. Biochem J. 414:19–29. 2008. View Article : Google Scholar : PubMed/NCBI
20	Cummins EP and Taylor CT: Hypoxia-responsive transcription factors. Pflugers Arch. 450:363–371. 2005. View Article : Google Scholar : PubMed/NCBI
21	Laver T, Nozell S and Benveniste EN: The NF-κB signaling pathway in GBMs: implications for apoptotic and inflammatory responses and exploitation for therapy. CNS Cancer, Cancer Drug Discovery and Development. Van Meir EG: Springer; pp. 1011–1036. 2009
22	Gilmore TD: Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 25:6680–6684. 2006. View Article : Google Scholar : PubMed/NCBI
23	Perkins ND: The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci. 25:434–440. 2000. View Article : Google Scholar : PubMed/NCBI
24	Perkins ND and Gilmore TD: Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 13:759–772. 2006. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
26	Lee CH, Jeon YT, Kim SH and Song YS: NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 29:19–35. 2007. View Article : Google Scholar : PubMed/NCBI
27	Sethi G, Sung B and Aggarwal BB: Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood). 233:21–31. 2008. View Article : Google Scholar : PubMed/NCBI
28	Van Waes C: Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res. 13:1076–1082. 2007.PubMed/NCBI
29	Reitman ZJ and Yan H: Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 102:932–941. 2010. View Article : Google Scholar : PubMed/NCBI
30	Dolcet X, Llobet D, Pallares J and Matias-Guiu X: NF-κB in development and progression of human cancer. Virchows Arch. 446:475–482. 2005.
31	Scortegagna M, Cataisson C, Martin RJ, et al: HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood. 111:3343–3354. 2008. View Article : Google Scholar : PubMed/NCBI
32	Cockman ME, Lancaster DE, Stolze IP, et al: Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci USA. 103:14767–14772. 2006. View Article : Google Scholar
33	Cummins EP, Berra E, Comerford KM, et al: Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA. 103:18154–18159. 2006. View Article : Google Scholar : PubMed/NCBI
34	Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell. 109(Suppl): S81–S96. 2002. View Article : Google Scholar : PubMed/NCBI
35	Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
36	Abdullah JM, Ahmad F, Ahmad KA, et al: Molecular genetic analysis of BAX and cyclin D1 genes in patients with malignant glioma. Neurol Res. 29:239–242. 2007. View Article : Google Scholar : PubMed/NCBI
37	Arato-Ohshima T and Sawa H: Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility. Int J Cancer. 83:387–392. 1999. View Article : Google Scholar : PubMed/NCBI
38	Zhang X, Zhao M, Huang AY, et al: The effect of cyclin D expression on cell proliferation in human gliomas. J Clin Neurosci. 12:166–168. 2005. View Article : Google Scholar : PubMed/NCBI
39	Liao DJ, Thakur A, Wu J, Biliran H and Sarkar FH: Perspectives on c-Myc, cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit Rev Oncog. 13:93–158. 2007. View Article : Google Scholar : PubMed/NCBI
40	Robson S, Pelengaris S and Khan M: c-Myc and downstream targets in the pathogenesis and treatment of cancer. Recent Pat Anticancer Drug Discov. 1:305–326. 2006. View Article : Google Scholar : PubMed/NCBI
41	Nobusawa S, Watanabe T, Kleihues P and Ohgaki H: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 15:6002–6007. 2009. View Article : Google Scholar : PubMed/NCBI
42	Houillier C, Wang X, Kaloshi G, et al: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 75:1560–1566. 2010. View Article : Google Scholar : PubMed/NCBI
43	SongTao Q, Lei Y, Si G, et al: IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 103:269–273. 2012. View Article : Google Scholar : PubMed/NCBI
44	Lee SM, Koh HJ, Park DC, et al: Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med. 32:1185–1196. 2002.
45	Rohle D, Popovici-Muller J, Palaskas N, et al: An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 340:626–630. 2013. View Article : Google Scholar : PubMed/NCBI